3D Medicines Reports Stable Share Capital for June 2026; 258.18 Million Shares in Issue, Public Float Maintained

Bulletin Express

Jul 07

On 2 July 2026, 3D Medicines Inc. (HKEX: 01244) submitted its Monthly Return for the period ended 30 June 2026, confirming no changes to capital structure or share count during the month.

• Authorised share capital remained at 500 million ordinary shares with a par value of HKD 0.001 each, equivalent to HKD 0.50 million in total.

• Issued share capital held steady at 258.18 million ordinary shares; the company held no treasury shares, and there were no share issuances, cancellations or transfers.

• Public float comfortably met the Main Board’s minimum 25% requirement as of 30 June 2026.

• The Share Option Scheme showed 12.80 million outstanding options, unchanged month-on-month, with no exercises or related share issuances. No warrants, convertible securities, or other share-issuing arrangements were outstanding.

Director Gong Zhaolong confirmed that all regulatory and listing rule obligations were met, and no new funds were raised during the reporting period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1144959046"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144959046\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144959046?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 12:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144959046","market":"us","top_or_hot":-1,"title":"3D Medicines Reports Stable Share Capital for June 2026; 258.18 Million Shares in Issue, Public Float Maintained","media":"Bulletin Express","content":"<p>On 2 July 2026, 3D Medicines Inc. (HKEX: 01244) submitted its Monthly Return for the period ended 30 June 2026, confirming no changes to capital structure or share count during the month.</p>\n<p>• Authorised share capital remained at 500 million ordinary shares with a par value of HKD 0.001 each, equivalent to HKD 0.50 million in total.</p>\n<p>• Issued share capital held steady at 258.18 million ordinary shares; the company held no treasury shares, and there were no share issuances, cancellations or transfers.</p>\n<p>• Public float comfortably met the Main Board’s minimum 25% requirement as of 30 June 2026.</p>\n<p>• The Share Option Scheme showed 12.80 million outstanding options, unchanged month-on-month, with no exercises or related share issuances. No warrants, convertible securities, or other share-issuing arrangements were outstanding.</p>\n<p>Director Gong Zhaolong confirmed that all regulatory and listing rule obligations were met, and no new funds were raised during the reporting period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3D Medicines Reports Stable Share Capital for June 2026; 258.18 Million Shares in Issue, Public Float Maintained</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3D Medicines Reports Stable Share Capital for June 2026; 258.18 Million Shares in Issue, Public Float Maintained\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-07 12:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 2 July 2026, 3D Medicines Inc. (HKEX: 01244) submitted its Monthly Return for the period ended 30 June 2026, confirming no changes to capital structure or share count during the month.</p>\n<p>• Authorised share capital remained at 500 million ordinary shares with a par value of HKD 0.001 each, equivalent to HKD 0.50 million in total.</p>\n<p>• Issued share capital held steady at 258.18 million ordinary shares; the company held no treasury shares, and there were no share issuances, cancellations or transfers.</p>\n<p>• Public float comfortably met the Main Board’s minimum 25% requirement as of 30 June 2026.</p>\n<p>• The Share Option Scheme showed 12.80 million outstanding options, unchanged month-on-month, with no exercises or related share issuances. No warrants, convertible securities, or other share-issuing arrangements were outstanding.</p>\n<p>Director Gong Zhaolong confirmed that all regulatory and listing rule obligations were met, and no new funds were raised during the reporting period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01244","symbol_name":"思路迪医药股份","start_time":0,"source_url":"","article_id":"1144959046","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144959046","pubTimestamp":1783397176,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 2 July 2026, 3D Medicines Inc. (HKEX: 01244) submitted its Monthly Return for the period ended 30 June 2026, confirming no changes to capital structure or share count during the month. •...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01244":"思路迪医药股份"},"translate_title":"3D Medicines报告2026年6月股本稳定；已发行2.5818亿股，公众持股量保持不变","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01244":1},"content_text":"On 2 July 2026, 3D Medicines Inc. (HKEX: 01244) submitted its Monthly Return for the period ended 30 June 2026, confirming no changes to capital structure or share count during the month.\n• Authorised share capital remained at 500 million ordinary shares with a par value of HKD 0.001 each, equivalent to HKD 0.50 million in total.\n• Issued share capital held steady at 258.18 million ordinary shares; the company held no treasury shares, and there were no share issuances, cancellations or transfers.\n• Public float comfortably met the Main Board’s minimum 25% requirement as of 30 June 2026.\n• The Share Option Scheme showed 12.80 million outstanding options, unchanged month-on-month, with no exercises or related share issuances. No warrants, convertible securities, or other share-issuing arrangements were outstanding.\nDirector Gong Zhaolong confirmed that all regulatory and listing rule obligations were met, and no new funds were raised during the reporting period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}